Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, randomized, double-blind, phase III efficacy study comparing phenoxodiol in combination with carboplatin versus carboplatin with placebo in patients with platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian or primary peritoneal cancer following at least second line platinum therapy.

Next Previous
Trial Profile

Multi-center, randomized, double-blind, phase III efficacy study comparing phenoxodiol in combination with carboplatin versus carboplatin with placebo in patients with platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian or primary peritoneal cancer following at least second line platinum therapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary) ; Carboplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OVATURE
  • Sponsors Lite Strategy; MEI Pharma

Most Recent Events

  • 10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
  • 14 Apr 2012 Planned number of patients changed from 340 to 470 as reported by European Clinical Trials Database record.
  • 03 Feb 2012 Additional lead trial investigator identifed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top